🔍
Search Results - technology+classifications+%3e+therapeutic+modalities+%3e+proteins
34
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Bicistronic Genes and Fusion Proteins for Immune Activation
Value Proposition:· Dual specific targeting for improved full T-cell and amplification.· Interchangeable protein components can be customized for cancer, infectious disease, and autoimmune disorder therapies.· Deliverable by nanoparticles into cells in vivo, in vitro, and ex vivo for immune activation.Unmet Need:Immunotherapy is a rapidly...
Published: 3/13/2026
|
Inventor(s):
Jordan Green
,
Joanna Yang
,
Stephany Tzeng
,
Jamie Spangler
Keywords(s):
Category(s):
Technology Classifications > Therapeutic Modalities > Gene Therapies
,
Technology Classifications > Therapeutic Modalities > Immunotherapies
,
Technology Classifications > Therapeutic Modalities > Proteins
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
,
Technology Classifications > Research Tools > Vectors & Plasmids
,
Technology Classifications > Research Tools > Proteins, Ligands & Receptors
,
Technology Classifications > Research Tools > Nucleic Acids
Combinations of ASOs for the Modulation of SMN Expression in SMA Patients
Unmet NeedSpinal muscular atrophy (SMA) is a devastating neuromuscular disease that predominantly affects children and is the most common cause of hereditary infant mortality. The disease is caused by low levels of survival motor neuron (SMN) protein, due to recessive mutations in the SMN1 gene. Importantly, the copy number variation of SMN2, a homologous...
Published: 3/13/2026
|
Inventor(s):
Charlotte Sumner
,
Constantin d'Ydewalle
,
Frank Rigo
,
C. Bennett
Keywords(s):
CNS and Neurological Disorders
,
Combination
,
Disease Indication
,
Drug Delivery Vehicle
,
Muscle Atrophy
,
Muscular Disorders
,
Neurodegenerative Diseases
,
Peptides/Prodrugs
,
Single
,
Targeted Therapy
,
Therapeutic Matter
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations > Neurology > Motor Neuron Diseases
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
,
Technology Classifications > Therapeutic Modalities > Proteins
Mimetic peptides derived from collagen type IV for the treatment of angiogenesis-dependent diseases
C11348: Novel Anti-Angiogenic Collagen Derived Mimetic PeptidesNovelty:modified peptides from collagen IV derived parent peptide Pentastatin-1Value Proposition:The invention describes the synthesis of novel anti-angiogenic by substituting particular amino acids of the peptide Pentastatin-1 derived from collagen IV. Other advantages include:• Ability...
Published: 3/12/2026
|
Inventor(s):
Niranjan Pandey
,
Elena Rosca
,
Corban Rivera
,
Jacob Koskimaki
,
Amir Tamiz
,
Aleksander Popel
Keywords(s):
Biologics
,
Cancers
,
Disease Indication
,
Peptide
,
Protein
,
Single
,
Targeted Therapy
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
,
Therapy Type
Category(s):
Clinical and Disease Specializations
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Proteins
,
Technology Classifications > Therapeutic Modalities > Targets
,
Technology Classifications > Therapeutic Modalities
A method for inhibiting UHRF1 in colorectal cancer
Value PropositionReversal of colorectal cancer-specific DNA hypermethylationmRNA-based strategy for UHRF1 inhibitionA lipid nanoparticle-based delivery platformUnmet Need1 out of 24 people will develop colorectal cancer. Current technologies do not maximize the bodies’ native ability to suppress tumors. Existing therapies lack specificity and cause...
Published: 3/13/2026
|
Inventor(s):
Stephen Baylin
,
Srinivasan Yegnasubramanian
,
Ying Cui
,
Xiangqian Kong
Keywords(s):
Category(s):
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
,
Technology Classifications > Research Tools > Nucleic Acids
,
Technology Classifications > Therapeutic Modalities > Peptides
,
Technology Classifications > Therapeutic Modalities > Proteins
,
Technology Classifications > Research Tools > Proteins, Ligands & Receptors
A Method to Conditionally Deliver Effector Proteins to Plasma and Endosomal Membranes in Response to Tyrosine Kinase Signaling
Value Proposition· Effective & Targeted: Harnesses endogenous pain signaling via receptor tyrosine kinases to conditionally deliver effector proteins to the plasma membrane, enabling suppression of chronic pain under pathological conditions· Broadly Applicable: Enables modular, tunable therapy tailored to the prevailing pathological...
Published: 3/13/2026
|
Inventor(s):
Michael Caterina
,
Stephen Gould
,
Shang-Jui Tsai
Keywords(s):
Category(s):
Clinical and Disease Specializations > Pain > Chronic Pain
,
Technology Classifications > Therapeutic Modalities > Proteins
,
Clinical and Disease Specializations > Neurology
,
Clinical and Disease Specializations > Oncology
Method for Surface Expression of Membrane Proteins that have a Cytoplasmic C-terminal Tail
Enhanced Vaccine Development through Optimized Antigen DisplayJHU Ref #: C16777Value Proposition· Improved antigenicity due to increased cell surface expression of viral proteins · Boosts vaccine efficacy · Potential for integration into various vaccine platforms, including viral-mediated, mRNA-mediated, and DNA-mediated vaccines Unmet...
Published: 3/13/2026
|
Inventor(s):
Stephen Gould
,
Linda Marban
,
Chenxu Guo
,
Shang-Jui Tsai
Keywords(s):
Category(s):
Technology Classifications > Therapeutic Modalities > Proteins
,
Technology Classifications > Therapeutic Modalities > Vaccines
mRNA Intensifier to treat Haploinsufficiencies
Unmet Need / Invention Novelty: Haploinsufficiency occurs when one gene allele is inactivated and the amount of gene product expressed from the remaining active allele is insufficient for proper gene function. Targeted restoration of mRNA expression and translation may offer a therapeutic window. Technical Details: Johns Hopkins researchers designed...
Published: 3/13/2026
|
Inventor(s):
Jeffery Coller
,
Bahareh Torkzaban
Keywords(s):
Category(s):
Technology Classifications > Therapeutic Modalities > Gene Therapies
,
Technology Classifications > Therapeutic Modalities > Proteins
Compositions of Kinetic Nanoparticles containing Nucleic Acids, Polycations, and Lipids with Defined Sizes, and Methods of Producing the Same
Value Proposition:· Scalable, efficient, and tunable nanoparticle creation technique that can deliver a variety of payloads· Polymer-lipid nanoparticles are biodegradable and are being tested for immunogenicity· Can be used for in vivo gene therapy delivery as well as in vitro cell transfection and research applications Technology...
Published: 3/13/2026
|
Inventor(s):
Hai-Quan Mao
,
Stephany Tzeng
,
Jordan Green
,
Yizong Hu
,
Sashank Reddy
,
Leonardo Cheng
Keywords(s):
Category(s):
Clinical and Disease Specializations > Immuno-Oncology
,
Clinical and Disease Specializations > Oncology
,
Technology Classifications > Engineering Tech > Materials
,
Technology Classifications > Research Tools > Nucleic Acids
,
Technology Classifications > Research Tools > Peptides
,
Technology Classifications > Research Tools > Vectors & Plasmids
,
Technology Classifications > Therapeutic Modalities > Gene Therapies
,
Technology Classifications > Therapeutic Modalities > Peptides
,
Technology Classifications > Therapeutic Modalities > Proteins
,
Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms
The Efficacy of Nanozyme in Neurodegenerative Diseases
Unmet NeedOxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a cure. Technology OverviewDisclosed herein are novel...
Published: 3/13/2026
|
Inventor(s):
Xiaobo Mao
,
Shuya Li
,
Weiwei He
Keywords(s):
Category(s):
Clinical and Disease Specializations > Neurology > Alzheimer's Disease
,
Clinical and Disease Specializations > Neurology > Neurodegeneration
,
Clinical and Disease Specializations > Neurology > Parkinson's Disease
,
Clinical and Disease Specializations > Neurology > Parkinson’s Disease
,
Technology Classifications > Therapeutic Modalities > Proteins
Transgenic Fungi that Kill Malaria Parasites in Mosquitoes
Invention novelty: This material is a transgenic fungus which targets the sporozoites that cause malaria in the salivary glands of mosquitoes. The fungus is taken up by direct contact with the mosquito and inhibits Plasmodium development. Value Proposition: Unmodified, Metarhizium anisopliae kills mosquitoes slowly. If mosquitoes are infected by the...
Published: 3/12/2026
|
Inventor(s):
Raymond St. Leger
,
Angray Kang
,
Weiguo Fang
,
Marcelo Jacobs-Lorena
Keywords(s):
Biologics
,
Disease Indication
,
Disease Management System
,
Healthcare Management
,
Infectious Diseases
,
Malaria
,
Operations Management
,
Parasitic Infections
,
Protein
,
Therapeutic Matter
,
Therapeutic Substance
,
Therapeutics
Category(s):
Clinical and Disease Specializations
,
Technology Classifications > Computers, Electronics & Software > Clinical Management
,
Technology Classifications > Computers, Electronics & Software > Healthcare IT
,
Technology Classifications > Therapeutic Modalities > Biologics
,
Technology Classifications > Therapeutic Modalities > Proteins
,
Technology Classifications > Computers, Electronics & Software
,
Clinical and Disease Specializations > Infectious Diseases
,
Technology Classifications > Therapeutic Modalities
,
Clinical and Disease Specializations > Infectious Diseases > Malaria
,
Clinical and Disease Specializations > Infectious Diseases > Parasitic Infections
1
2
3
4
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum